DOI QR코드

DOI QR Code

RECK Gene Promoter rs10814325 Polymorphism in Egyptian Patients with Hepatocellular Carcinoma on Top of Chronic Hepatitis C Viral Infection

  • Fakhry, Amal Bahgat (Department of Clinical and Chemical Pathology, Kasr Al-Aini School of Medicine, Cairo University) ;
  • Ahmed, Asmaa Ismail (Department of Clinical and Chemical Pathology, Kasr Al-Aini School of Medicine, Cairo University) ;
  • AbdelAlim, Mahmoud Abdo (Department of Hepatology and Endemic Medicine, Kasr Al-Aini School of Medicine, Cairo University) ;
  • Ramadan, Dalia Ibrahim (Department of Clinical and Chemical Pathology, Kasr Al-Aini School of Medicine, Cairo University)
  • Published : 2016.05.01

Abstract

Background: The reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) gene is a novel transformation suppressor gene linked to several malignancies. Objective: To analyze any association between RECK gene rs10814325 single-nucleotide polymorphism (SNP) and HCC susceptibility with various clinicopathological and laboratory data. Materials and Methods: RECK gene rs10814325 SNP was estimated, using real-time PCR, in 30 HCC patients on top of HCV infection, 30 HCV related cirrhotic patients and 30 healthy controls. Results: No special pattern of association could be detected on comparing the RECK gene rs10814325 genotypes(P=0.5), or alleles(P=0.49) among the studied groups. HCC patients with TT genotype had younger age (mean of $54.1{\pm}6.0$ years vs $60.6{\pm}10.2$ years for TC/CC genotypes, P=0.035). Abdominal distension was significantly greater in TT genotype patients (75% vs 30%for TC/CC genotypes, P=0.045). The TT genotype was present in 75% of patients with lymph node metastasis. Serum GGT levels were higher in TT genotype patients [80 (48.5-134.8) IU/L vs 40 (33-87.5) IU/L for TC/CCgenotypes], and lower limb edema was observed in 60% for TT vs 20% for TC/CCgenotypes, but both just failed to reach significance (p=0.05 and p=0.06 respectively). Conclusions: RECK gene rs10814325 T>C could not be considered a risk factor for HCC development on top of HCV, but may be related to the disease progression and metastasis.

Keywords

Hepatocellular carcinoma;HCV related-cirrhosis;RECK gene;gene polymorphism;real time PCR

Acknowledgement

Supported by : Cairo University

References

  1. Alexius-Lindgren M, Andersson E, Lindstedt I, et al ( 2014). The RECK gene and biological malignancy--its significance in angiogenesis and inhibition of matrix metalloproteinases. Anticancer Res, 34, 3867-73.
  2. Bakiri L, Wagner EF (2013). Mouse models for liver cancer. Mol Oncol, 7, 206 - 23 https://doi.org/10.1016/j.molonc.2013.01.005
  3. Chen X, Jiang F, Shi N, et al (2014). RECK Gene polymorphisms influence NSCLC susceptibility, but not the chemotherapy response status in Chinese Cohort. Cell Biochem Biophys, 69, 567-71. https://doi.org/10.1007/s12013-014-9832-8
  4. Chen TY, Li YC, Liu YF, et al.(2011) Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol, 18, 2348-56. https://doi.org/10.1245/s10434-011-1574-x
  5. Chung TT, Pan MS, Kuo CL, et al (2011) Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis, 32, 1063-8. https://doi.org/10.1093/carcin/bgr083
  6. Chung TT, Yeh CB, Li YC, et al (2012). Effect of RECK Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features. Plos One, 7, 33517. https://doi.org/10.1371/journal.pone.0033517
  7. Clark JCM, Thomas DM, Choong PFM, et al (2007) RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Met Rev.,26:675-83. https://doi.org/10.1007/s10555-007-9093-8
  8. Du YY, Dai DQ, Yang Z (2010). Role of RECK methylation in gastric cancer and its clinical significance. World J Gastroenterol, 16, 904-8.
  9. Eisenberg I, Hochner H, Sadeh M, et al (2002). Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene. Cytogenet Genome Res, 97, 58-61. https://doi.org/10.1159/000064042
  10. El-Serag HB, Kanwal F (2014). Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatol, 60, 1767-75. https://doi.org/10.1002/hep.27222
  11. Kato N, Ji G, Wang Y, et al (2005). Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatol, 42, 846-53. https://doi.org/10.1002/hep.20860
  12. Lavanchy D (2011). Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 17, 107-15. https://doi.org/10.1111/j.1469-0691.2010.03432.x
  13. Lei H, Hemminki K, Altieri A, et al (2007). Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat, 103, 61-9. https://doi.org/10.1007/s10549-006-9345-2
  14. Liu W, Tian F, Dai L, et al (2014). Cytochrome P450 2E1 gene polymorphism and alcohol drinking on the risk of hepatocellular carcinoma: a meta-analysis. Mol Biol Rep, 41, 7645-50. https://doi.org/10.1007/s11033-014-3655-y
  15. Masui T, Doi R, Koshiba T, et al (2003). RECK Expression in Pancreatic Cancer: Its Correlation with Lower Invasiveness and Better Prognosis. Clin Cancer Res, 9, 1779-84.
  16. Meng N, Li Y, Zhang H, et al (2008). Review: RECK, a novel matrix metalloproteinase regulator. Histol Histopathol, 23, 1003-10.
  17. Mlynarsky L, Menachem Y, Shibolet O (2015). Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol, 7, 566-74. https://doi.org/10.4254/wjh.v7.i3.566
  18. Mohd Hanafiah K, Groegar J, Flaxman AD, et al (2013). Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatol, 57, 1333-42. https://doi.org/10.1002/hep.26141
  19. Morgan TR, Mandayam S, Jamal MM (2004). Alcohol and hepatocellular carcinoma. Gastroentrol, 127, 87-96. https://doi.org/10.1053/j.gastro.2004.09.020
  20. Omata M, Kanda T, Yu ML, et al (2012). APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int, 6, 409-35. https://doi.org/10.1007/s12072-012-9342-y
  21. Shiraha H, Yamamoto K, Namba M (2013). Human hepatocyte carcinogenesis. Int J Oncol, 42, 1133-8. https://doi.org/10.3892/ijo.2013.1829
  22. Tateyama M, Yatsuhashi H, Taura N, et al (2011). Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol, 46, 92-100. https://doi.org/10.1007/s00535-010-0293-6
  23. Wang Y, Kato N, Hoshida Y, et al (2004). UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res, 10, 2441-6. https://doi.org/10.1158/1078-0432.CCR-1187-3
  24. Weng CJ, Hsieh YH, Tsai CM, et al (2010). Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol, 17, 1808-15. https://doi.org/10.1245/s10434-009-0904-8
  25. Weng CJ, Tsai CM, Chen YC, et al (2010). Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol, 17, 3394-401. https://doi.org/10.1245/s10434-010-1124-y
  26. Zhang Y, Deng ZS, Liao MM, et al (2012). Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. Pathol Oncol Res, 18, 911-6. https://doi.org/10.1007/s12253-012-9521-0